Supplementary Figure Legend from Loss of Fas Expression and Function is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy

Wei Xiao,Mohammed L. Ibrahim,Priscilla S. Redd,John D. Klement,Chunwan Lu,Dafeng Yang,Natasha M. Savage,Kebin Liu

DOI: https://doi.org/10.1158/1541-7786.22516092.v1

2023-01-01

Abstract:Supplemental Figure Legends 1-5

What problem does this paper attempt to address?

Supplementary Figure Legends from Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells

Rajat Bhattacharya,Xiang-Cang Ye,Rui Wang,Xia Ling,Madonna McManus,Fan,Delphine Boulbes,Lee M. Ellis

DOI: https://doi.org/10.1158/0008-5472.22407995.v1

2023-01-01

Abstract:Legends for Supplementary Figures S1-S12.
Figure S2 from Loss of Fas Expression and Function is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy

Wei Xiao,Mohammed L. Ibrahim,Priscilla S. Redd,John D. Klement,Chunwan Lu,Dafeng Yang,Natasha M. Savage,Kebin Liu

DOI: https://doi.org/10.1158/1541-7786.22516104.v1

2023-01-01

Abstract:Loss of Fas function leads to resistance to FasL-induced apoptosis.
Figure S1 from Loss of Fas Expression and Function is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy

Wei Xiao,Mohammed L. Ibrahim,Priscilla S. Redd,John D. Klement,Chunwan Lu,Dafeng Yang,Natasha M. Savage,Kebin Liu

DOI: https://doi.org/10.1158/1541-7786.22516107.v1

2023-01-01

Abstract:Figure S1. Sensitivity of colon carcinoma cell lines to FasL-induced apoptosis in vitro.
Supplementary Figure Legends and Supplementary Figures 1 Through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

Xiaohui Fan,Randall J. Brezski,Hui Deng,Pooja Dhupkar,Yun Q. Shi,Anneliese Gonzalez,Songlin Zhang,Michael A. Rycyzyn,William R. Strohl,Robert E. Jordan,Ningyan Zhang,Zhiqiang An

DOI: https://doi.org/10.1158/1535-7163.22501711

2023-01-01

Abstract:Figure S1: IdeS expression in BT474 breast cancer cells Figure S2: Detection of MMPs in cancer cell lysates and culture supernatant Figure S3: scIgG-T was not in the SKBR-3 cell culture medium Figure S4: Detection of immune cells infiltration in mice by flow cytometry.
Figure S3 from Loss of Fas Expression and Function is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy

Wei Xiao,Mohammed L. Ibrahim,Priscilla S. Redd,John D. Klement,Chunwan Lu,Dafeng Yang,Natasha M. Savage,Kebin Liu

DOI: https://doi.org/10.1158/1541-7786.22516101.v1

2023-01-01

Abstract:FasL induces apoptosis to increase the frequency of colon cancer stem cell-like cells in MSS colon cancer cells.
Figure S5 from Loss of Fas Expression and Function is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy

Wei Xiao,Mohammed L. Ibrahim,Priscilla S. Redd,John D. Klement,Chunwan Lu,Dafeng Yang,Natasha M. Savage,Kebin Liu

DOI: https://doi.org/10.1158/1541-7786.22516095

2023-01-01

Abstract:Overexpression of Fas does not alter sphere formation.
Figure S4 from Loss of Fas Expression and Function is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy

Wei Xiao,Mohammed L. Ibrahim,Priscilla S. Redd,John D. Klement,Chunwan Lu,Dafeng Yang,Natasha M. Savage,Kebin Liu

DOI: https://doi.org/10.1158/1541-7786.22516098.v1

2023-01-01

Abstract:CD133+CD24loFaslo colon cancer stem cell-like cells exhibit increased invasiveness in vitro.
Supplemental Figure Legend from LIGHT Elevation Enhances Immune Eradication of Colon Cancer Metastases

Guilin Qiao,Jianzhong Qin,Nicholas Kunda,Jed F. Calata,Dolores L. Mahmud,Peter Gann,Yang-Xin Fu,Steven A. Rosenberg,Bellur S. Prabhakar,Ajay V. Maker

DOI: https://doi.org/10.1158/0008-5472.22415712.v1

2023-01-01

Abstract:Supplemental Figure Legend from LIGHT Elevation Enhances Immune Eradication of Colon Cancer Metastases
Supplementary Figures Legends from Qa-1<sup>b</sup> Modulates Resistance to Anti–PD-1 Immune Checkpoint Blockade in Tumors with Defects in Antigen Processing

Xiao Zhang,Erich Sabio,Chirag Krishna,Xiaojing Ma,Jingming Wang,Hui Jiang,Jonathan J. Havel,Timothy A. Chan

DOI: https://doi.org/10.1158/1541-7786.22526916.v1

2023-01-01

Abstract:Supplemental Figure Legends 1-4
Supplementary Figure Legends from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

Pei-Ling Chen,Whijae Roh,Alexandre Reuben,Zachary A. Cooper,Christine N. Spencer,Peter A. Prieto,John P. Miller,Roland L. Bassett,Vancheswaran Gopalakrishnan,Khalida Wani,Mariana Petaccia de Macêdo,Jacob L. Austin-Breneman,Hong Jiang,Qing Chang,Sangeetha M. Reddy,Wei-Shen Chen,Michael T. Tetzlaff,Russell Broaddus,Michael A. Davies,Jeffrey E. Gershenwald,Lauren E. Haydu,Alexander J. Lazar,Sapna P. Patel,Patrick Hwu,Wen‐Jen Hwu,Adi Diab,Isabella C. Glitza,Scott E. Woodman,Luis M. Vence,Ignacio I. Wistuba,Rodabe N. Amaria,Lawrence N. Kwong,Víctor G. Prieto,R. Eric Davis,Wencai Ma,Willem W. Overwijk,Arlene H. Sharpe,Jianhua Hu,P. Andrew Futreal,Jorge Blando,Padmanee Sharma,James P. Allison,Lynda Chin,Jennifer A. Wargo

DOI: https://doi.org/10.1158/2159-8290.22531188.v1

2023-01-01

Abstract:Supplementary Figure Legends
Supplementary Figure Legends from EpCAM Inhibition Sensitizes Chemoresistant Leukemia to Immune Surveillance

Xin Zheng,Xiaolei Fan,Binqing Fu,Ming–Hua Zheng,Aimei Zhang,Kai Zhong,Jun Yan,Rui Sun,Zhigang Tian,Wei H

DOI: https://doi.org/10.1158/0008-5472.22414839.v1

2023-01-01

Abstract:Supplementary Figure 1-6 legends
Supplementary Figure Legends from Mir-124 Inhibits STAT3 Signaling to Enhance T Cell–Mediated Immune Clearance of Glioma

Jun Wei,Fei Wang,Ling-Yuan Kong,Shuo Xu,Tiffany Doucette,Sherise D. Ferguson,Yuhui Yang,Kayla McEnery,Krishan Jethwa,Olsi Gjyshi,Wei Qiao,Nicholas B. Levine,Frederick F. Lang,Ganesh Rao,Gregory N. Fuller,George A. Calin,Amy B. Heimberger

DOI: https://doi.org/10.1158/0008-5472.22394862.v1

2023-01-01

Abstract:Supplementary Figure Legends - PDF file 70K, Supplementary Figure Legends
Supplementary Figure Legend from CCL9 Induced by TGFβ Signaling in Myeloid Cells Enhances Tumor Cell Survival in the Premetastatic Organ

Hangyi H. Yan,Jiang Jian,Yanli Pang,B.R. Achyut,Michael M. Lizardo,Xinhua Liu,Kent W. Hunter,Chand Khanna,Christine M. Hollander,Li Yang

DOI: https://doi.org/10.1158/0008-5472.22407863

2023-01-01

Abstract:Legend for Supplementary Figures S1-S6.
Supplementary Figure Legends from Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer

Li Liu,Xue Bai,Jian Wang,Xiaonan Tang,Dehua Wu,Shasha Du,Xiu-Ju Du,Yao-Wei Zhang,Hai‐Liang Zhu,Yuan Fang,Zhimou Guo,Qiandong Zeng,Xuejun Guo,Zhu Li,Zhong‐Yi Dong

DOI: https://doi.org/10.1158/1078-0432.22471917.v1

2023-01-01

Abstract:Supplementary figure legends
Loss of Fas Expression and Function is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy.

Wei Xiao,Mohammed L. Ibrahim,Priscilla S. Redd,John D. Klement,Chunwan Lu,Dafeng Yang,Natasha M. Savage,Kebin Liu

DOI: https://doi.org/10.1158/1541-7786.mcr-18-0455

2019-01-01

Molecular Cancer Research

Abstract:Abstract Despite the remarkable efficacy of immune checkpoint inhibitor (ICI) immunotherapy in various types of human cancers, colon cancer, except for the approximately 4% microsatellite-instable (MSI) colon cancer, does not respond to ICI immunotherapy. ICI acts through activating CTLs that use the Fas–FasL pathway as one of the two effector mechanisms to suppress tumor. Cancer stem cells are often associated with resistance to therapy including immunotherapy, but the functions of Fas in colon cancer apoptosis and colon cancer stem cells are currently conflicting and highly debated. We report here that decreased Fas expression is coupled with a subset of CD133+CD24lo colon cancer cells in vitro and in vivo. Consistent of the lower Fas expression level, this subset of CD133+CD24loFaslo colon cancer cells exhibits decreased sensitivity to FasL-induced apoptosis. Furthermore, FasL selectively enriches CD133+CD24loFaslo colon cancer cells. CD133+CD24loFaslo colon cancer cells exhibit increased lung colonization potential in experimental metastatic mouse models and decreased sensitivity to tumor-specific CTL adoptive transfer and ICI immunotherapies. Interestingly, FasL challenge selectively enriched this subset of colon cancer cells in microsatellite-stable (MSS) but not in the MSI human colon cancer cell lines. Consistent with the downregulation of Fas expression in CD133+CD24lo cells, lower Fas expression level is significantly correlated with decreased survival in patients with human colon cancer. Implications: Our data determine that CD133+CD24loFaslo colon cancer cells are capable to evade Fas-FasL cytotoxicity of tumor-reactive CTLs and targeting this subset of colon cancer cells is potentially an effective approach to suppress colon cancer immune evasion.
Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Junying Zeng,Sharad Sharma,Yong‐Qing Zhou,Hang‐Ping Yao,Xing Hu,Ruiwen Zhang,Ming-Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22503690

2023-01-01

Abstract:PDF - 71K, Legends for Supplementary Figures 1 through 5.
Supplementary Figure Legends from Accelerated Tumor Growth Mediated by Sublytic Levels of Antibody-Induced Complement Activation is Associated with Activation of the PI3K/AKT Survival Pathway

Xiaohong Wu,Govind Ragupathi,Katherine S. Panageas,Feng Hong,Philip O. Livingston

DOI: https://doi.org/10.1158/1078-0432.22446662

2023-01-01

Abstract:Legend for supplementary figures - PDF file 62K, Supplementary Figure Legend
Supplementary Figure Legends from Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Zhong-Yi Dong,Wen-Zhao Zhong,Xu-Chao Zhang,Jian Su,Zhi Xie,Si-Yang Liu,Hai-Yan Tu,Hua-Jun Chen,Yue-Li Sun,Qing Zhou,Jin-Ji Yang,Xue-Ning Yang,Jia-Xin Lin,Hong-Hong Yan,Hao-Ran Zhai,Li-Xu Yan,Ri-Qiang Liao,Si-Pei Wu,Yi-Long Wu

DOI: https://doi.org/10.1158/1078-0432.22462077.v1

2023-01-01

Abstract:Supplementary Figure legends
Supplementary Figure Legends 1-4 from Cancer Immunotherapy Using in Vitro Genetically Modified Targeted Dendritic Cells

Huafeng Wei,Hao Wang,Bing Lu,Bohua Li,Sheng Hou,Weizhu Qian,Kexing Fan,Jianxin Dai,Jian Zhao,Yajun Guo

DOI: https://doi.org/10.1158/0008-5472.22375065.v1

2023-01-01

Abstract:Supplementary Figure Legends 1-4 from Cancer Immunotherapy Using In vitro Genetically Modified Targeted Dendritic Cells
Supplementary Figure Legends from NK Cell–Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines

Alena Cristina Jaime‐Ramirez,Elizabeth L. McMichael,SriVidya Kondadasula,Cassandra C. Skinner,Bethany L. Mundy-Bosse,Eric Luedke,Natalie Jones,Aruna Mani,Julie M. Roda,Volodymyr Karpa,Hong Li,Jilong Li,Saranya Elavazhagan,Krista M. La Perle,Alessandra C. Schmitt,Yanhui Lu,Xiaoli Zhang,Xueliang Pan,Hsaioyin Mao,Melanie E. Davis,David Jarjoura,Jonathan P. Butchar,Ming Poi,Mitch A. Phelps,Susheela Tridandapani,John C. Byrd,Michael A. Caligiuri,Robert J. Lee,William E. Carson

DOI: https://doi.org/10.1158/2326-6066.22538788

2023-01-01

Abstract:Supplementary Figure Legends

Supplementary Figure Legend from Loss of Fas Expression and Function is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy

Supplementary Figure Legends from Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells

Figure S2 from Loss of Fas Expression and Function is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy

Figure S1 from Loss of Fas Expression and Function is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy

Supplementary Figure Legends and Supplementary Figures 1 Through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

Figure S3 from Loss of Fas Expression and Function is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy

Figure S5 from Loss of Fas Expression and Function is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy

Figure S4 from Loss of Fas Expression and Function is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy

Supplemental Figure Legend from LIGHT Elevation Enhances Immune Eradication of Colon Cancer Metastases

Supplementary Figures Legends from Qa-1&lt;sup&gt;b&lt;/sup&gt; Modulates Resistance to Anti–PD-1 Immune Checkpoint Blockade in Tumors with Defects in Antigen Processing

Supplementary Figure Legends from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

Supplementary Figure Legends from EpCAM Inhibition Sensitizes Chemoresistant Leukemia to Immune Surveillance

Supplementary Figure Legends from Mir-124 Inhibits STAT3 Signaling to Enhance T Cell–Mediated Immune Clearance of Glioma

Supplementary Figure Legend from CCL9 Induced by TGFβ Signaling in Myeloid Cells Enhances Tumor Cell Survival in the Premetastatic Organ

Supplementary Figure Legends from Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer

Loss of Fas Expression and Function is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy.

Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Figure Legends from Accelerated Tumor Growth Mediated by Sublytic Levels of Antibody-Induced Complement Activation is Associated with Activation of the PI3K/AKT Survival Pathway

Supplementary Figure Legends from Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Supplementary Figure Legends 1-4 from Cancer Immunotherapy Using in Vitro Genetically Modified Targeted Dendritic Cells

Supplementary Figure Legends from NK Cell–Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines

Supplementary Figures Legends from Qa-1<sup>b</sup> Modulates Resistance to Anti–PD-1 Immune Checkpoint Blockade in Tumors with Defects in Antigen Processing